Oncimmune, a UK-based company, has launched EarlyCDT Lung test, a lung cancer early detection product based on the detection of 7 autoantibodies (CAGE, GBU4-5, HuD, MAGE A4, NY-ESO-1, p53, and SOX2) presenting in the sera of lung cancer patients. This evidence concerns the gene TP53 and lung carcinoma.